The Pharmaceutical Industry Looks to Reduce Waste by Getting Lean - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Pharmaceutical Industry Looks to Reduce Waste by Getting Lean
The low-volume pharmaceutical industry must adapt Lean Manufacturing tools invented for high-volume, single product industries.


Pharmaceutical Technology


Scott Geller
From regulatory compliance and globalization to production and pricing pressures, the pharmaceutical industry faces overwhelming demands to remain profitable and competitive. In light of indications that drug manufacturing currently wastes $50 billion per year, many companies are waking up to the value of creating more efficient operations (1).

Some have turned to traditional Lean Manufacturing practices to transform their operations from the high margin, low-productivity model of the past. Unfortunately, success has been elusive: traditional Lean practices are not well suited to pharma's complex, highly variable, shared-asset production environments.

Others have looked to technology to provide leaner, demand-based production. Our company recently surveyed manufacturing performance at 1500 pharmaceutical manufacturers. We found that—even after spending millions on enterprise resource planning (ERP) systems, advanced planning and scheduling (APS) systems, and other traditional technologies—many are still chasing performance improvements at the plant level. Only a third of those surveyed felt that their IT systems have delivered their expected ROI. Respondents cited lack of information visibility, no awareness of variability and lack of support for Lean principles.

Global visibility, global optimization




To achieve the benefits of Lean, manufacturers need global visibility of production performance and optimization and simulation solutions that help model scenarios for more-agile performance. They must battle manufacturing's performance killer: variability. Few industries deal with as much variability in products and processes as drug makers, whose product mix averages to 20% in new SKUs per year and to 60% in overall SKU volatility.

Most successful Lean implementations have been in high-volume, low-mix manufacturing, which isn't surprising given Lean's links in the automotive industry: the Toyota Production System. Implementing traditional Lean is a struggle in the pharmaceutical arena, where hundreds of products, dozens of work centers, and significantly more process and demand variability are the norm.

The good news is that this is changing. Next-generation optimization software and methodologies can adapt traditional Lean Manufacturing techniques to account for variability and mitigate its impact. By changing traditional performance metrics, using flow-path management to derive more flexible approaches to define value streams and organizational structure, and using alternate means of calculating inventory, capacity planning and lot sizing, companies such as Bristol-Myers Squibb have cut cycle times and inventory in half or more, while achieving on-time delivery rates as high as 99%.

Next-generation solutions

To begin reducing the $50 billion per year waste, manufacturers must leverage this Modified Lean approach and combine it with flow-based manufacturing methodologies, simulation and analytics software, and variations on demand-based pull scheduling. This next generation solution will enable companies to:

  • Break down organizational silos and integrate manufacturing operations. Decisions can be made on the basis of product flow through the factory, not by individual departmental metrics, improving control over key performance indicators.
  • Improve decisions that impact the bottom line. Improved real-time data are fed back into the ERP and other business systems for better visibility, planning, and decision-making. By feeding more accurate data from the plant floor into other business systems, manufacturers can slash inventory and reduce cycle times up to 80%.
  • Determine best-practices and prioritize metrics based on current business goals and challenges. Simulations allow manufacturers to model scenarios to answer questions such as Which scenario will enable me to reduce cycle times more effectively? and Where will reductions in variability benefit the bottom line most?

Scott Geller is president and CEO of Invistics, 5445 Triangle Parkway, Suite 300, Norcross, GA 30092, tel. 770.559.6386, fax 770.582.9298, http://www.invistics.com/.

Reference

1. J. Macher and J. Nickerson, "Pharmaceutical Manufacturing Research Project Final Benchmarking Report," Washington University in St. Louis, September 2006.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here